Formal clinical validation is still needed. But if multicenter trials confirm these results, the multiplex assay may be able to save time and resources by quickly testing for both tuberculous mycobacteria and NTM (including MAC), promoting accurate diagnosis and proper treatment of both. This could potentially benefit areas both with and without endemic tuberculosis.
Dr. Hickman is a medical writer based in Bloomington, Indiana.
Pages: 1 2 | Single Page
No Responses to “New Multiplex PCR Assay for Nontuberculous Mycobacteria Being Investigated”